Transgenic mice expressing human CD20 and/or CD16

Details Transgenic mice expressing human CD20 and/or CD16 Transgenic mice expressing human CD20 and/or CD16

2008-07-22

2008-07-22

Li, Q. Janice (Department: 1633)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S009000, C800S010000, C800S021000

Reexamination Certificate

active

10537963

ABSTRACT:
The present invention generally relates to non-human transgenic animals expressing human cellular markers, including CD20 and/or preferably CD16.

REFERENCES:
patent: 5859312 (1999-01-01), Littman et al.
patent: 2002/0064823 (2002-05-01), Welcher et al.
patent: 2002/0128448 (2002-09-01), Reff
patent: 1 452 093 (1994-09-01), None
patent: 95/15376 (1995-06-01), None
patent: 95/28959 (1995-11-01), None
patent: 99/00010 (1999-01-01), None
patent: WO 02/062946 (2002-08-01), None
Moreadith et al, J. Mol. Med., Mar. 1997;75(3):208-16.
Pera et al, Journal of Cell Science 2000;113: 5-10.
Logan et al, Clin Exp Pharmacol Physiol 1999;26:1020-5.
Denning, Nat Biotech 2001;19:559-562.
Smith and Murphy, Cloning Stem Cells 2004;6:126-32.
Polejaeva et al, Nature 2000;407:86-90.
Simerly et al, Science 2003;300:297.
Serfini et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease.Human Gene Therapy. Jan. 2004, vol. 15, pp. 63-76.
Kawanaka et al. Expression of Fc gamma receptor III (CD16 on monocytes during hemodialysis in patients with chronic renal failure.Nephron. Jan. 2002, vol. 90, No. 1, pp. 64-71.
Heijnen, I. et al. “Antigen targeting to myeloid-specific human Fc-gamma-RJ-CD64 triggers enhanced antibody responses in transgenic mice cd,” Journal of Clinical Investigation, 97(2):331-338, Jan. 1996.
Guyre, P. et al. “Increased potency Fc-receptor-targeted antigens,” Cancer Immunology Immunotherapy, 45(3-4):146-148, 1997.
Flamad, V. “Delayed maturation of CD4-CD8-Fc-Gamma-R11-I11+ T and natural killer cell precursors in Fc-Epsilon-R1-Gamma transgenic mice,” Journal of Experimental Medicine, 184(5):1725-1734, Nov. 1996.
Scharenberg, A. et al. “The FcRbeta subunit functions as an amplifier of Fc Rgamma mediated cell activation signal,” The Journal of Allergy and Clinical Immunology, 99(1, part 2):s406, Jan. 1997.
European Search Report mailed Apr. 3, 2006.
International Search Report mailed Aug. 6, 2004.
International Search Report mailed Feb. 23, 1999.
Arzoo et al., “Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)”,Ann. Rheum. Dis., 61:922-924 (2002).
Butler, “The Amplified ELISA: Principles of and Applications for the Comparative Quantitation of Class and Subclass Antibodies and the Distribution of Antibodies and Antigens in Biochemical Separates”,Methods in Enzymology. 73:482-523 (1981).
Capecchi, “Altering the Genome by Homologous Recombination”,Science, 244:1288-1292 (1989).
Capecchi, “The New Mouse Genetics: Altering the Genome by Gene Targeting”,TIG, 5(3):70-76 (1989).
Davis et al., “Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trail of Rituximab”,Journal of Clinical Oncology, 17(6):1851-1857 (1999).
Fleit et al., “A Soluble Form of FcγRIII is Present in Human Serum and Other Body Fluids and is Elevated at Sites of Inflammation”,Blood, 79(10):2721-2728 (1992).
Foran et al., “European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients with Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma. Immunocytoma. and Small B-Cell Lymphocytic Lymphoma”,Journal of Clinical Oncology, 18(2):317-324 (2000).
Gong et al., “Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy”,Journal of Immunology, 174(2):817-826 (2005).
Gopal et al., “Clinical applications of anti-CD20 antibodies”,J. Lab. Clin. Med., 134:445-450 (1999).
Kim et al., “Construction and Characterization of a Human Bacterial Artificial Chromosome Library”.Genomics, 34:213-218 (1996).
Mansour et al., “Disruption of the proto-oncogeneint-2in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes”,Nature, 336:348-352 (1988).
Mathiot et al., “Correlation Between Soluble Serum CD16 (sCD16) Levels and Disease Stage in Patients with Multiple Myeloma”,Journal of Clinical Immunology, 13(1):41-48 (1993).
Polyak et al., “Alanine-170 and Proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quatemary structure”,Blood, 99(9):3256-3262 (2002).
Protheroe et al., “Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma”,Rheumatology. 38:1150-1152 (1999).
Shizuya et al., “Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA inEscherichia coliusing an F-factor-based vector”,Proc. Natl. Acad. Sci. USA, 89:8794-8797 (1992).
Solal-Celigny et al., “Rituximab as First-Line Treatment of Patients with Follicular Lymphoma (FL) and a Low-Burden Tumor: Clinical and Molecular Evaluation”,Blood. 94(10):631a, Abstract #2802 (1999).
Swiatek et al., “Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger geneKrox20”, Genes&Development, 7:2071-2084 (1993).
Trape, “Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders”,Haematologica, 88:223-225 (2003).
Van de Winkel et al., “Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications”,Immunology Today, 14(5):215-221 (1993).
Weiner, “Monoclonal Antibody Therapy of Cancer”,Seminars in Oncology, 26(5)(Suppl. 14):43-51 (1999).
White et al., “Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma”,Pharm. Sci. Technol. Today, 2(3):95-101 (1999).
Zelenetz et al., “Iodine I 131 Tositumomab for Patients with Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL): Overall Clinical Trial Experience”,Blood, 94(10):632a. Abstract 2806 (1999).
GenBank Accession No. AH003353 dated Feb. 22, 1996.
GenBank Accession No. BC002807 dated Jul. 15, 2006.
GenBank Accession No. M62541 dated Jul. 26, 1993.
GenBank Accession No. P30273 dated Jun. 13, 2006.
GenBank Accession No. M27394 dated Jul. 15, 1993.
GenBank Accession No. M27395 datd Feb. 22, 1996.
GenBank Accession No. NM—010188 dated Jun. 12, 2006.
GenBank Accession No. NM—000569 dated Jul. 16, 2006.
GenBank Accession No. NM—000570 dated Jul. 2, 2006.
GenBank Accession No. Z46222 dated Apr. 18, 2005.
GenBank Accession No. Z46223 dated Mar. 20, 1997.
Supplementary Partial European Search Report dated May 22, 2006.
Cameron, 1997,MolecularBiology 7:253-265 “Recent Advances in Transgenic Technology”.
Hammer et al., 1986,Journal of Animal Science63:269-278 “Genetic Engineering of Mammalian Embryos”.
Houdebine, 1994,J. Biotech. 34:269-287 “Production of pharmaceutical proteins from transgenic animals”.
Kappell et al., 1992,Current Opinion in Biotechnology3:548-553 “Regulating gene expression in transgenic animals”.
Mullins et al., 1993,Hypertension22:630-633 “Transgenesis in nonmurine species”.
Mullins et al., 1996,Journal of Clinical Investment98:S37-S40 “Perspectives Series: Molecular Medicine in Genetically Engineered Animals: Transgenesis in the Rat and Larger Mammals”.
Niemann, 1998,Transgenic Research7:73-75 “Transgenic farm animals get off the ground”.
Sigmund, 2000,Arterioscler Thromb. Vasc. Boil. 20:1425-1429 “Viewpoint: Are Studies in Genetically Altered Mice Out of Control?”.
Wall, 1996,Theriogenology45:57-68 “Transgenic Livestock: Progress and Prospects for the Future”.
Wall, 1997,Journal of DairyScience 80(9):2213-2224 “Transgenic Dairy Cattle: Genetic Engineering on a Large Scale”.
Wilmut, 2003,Cloning

Affiliated with

Also associated with

Rating

Transgenic mice expressing human CD20 and/or CD16 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transgenic mice expressing human CD20 and/or CD16, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mice expressing human CD20 and/or CD16 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3918782